Cargando…
Immunomodulatory Effects of IFNα on T and NK Cells in Chronic Myeloid Leukemia Patients in Deep Molecular Response Preparing for Treatment Discontinuation
A deep and stable molecular response (DMR) is a prerequisite for a successful treatment-free remission (TFR) in chronic myeloid leukemia (CML). In order to better identify and analyze potential candidates of successful TFR, we examined the phenotypic and functional host immune compartment in DMR pat...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9570842/ https://www.ncbi.nlm.nih.gov/pubmed/36233461 http://dx.doi.org/10.3390/jcm11195594 |
_version_ | 1784810211312140288 |
---|---|
author | Puzzolo, Maria Cristina Breccia, Massimo Mariglia, Paola Colafigli, Gioia Pepe, Sara Scalzulli, Emilia Mariggiò, Elena Latagliata, Roberto Guarini, Anna Foà, Robin |
author_facet | Puzzolo, Maria Cristina Breccia, Massimo Mariglia, Paola Colafigli, Gioia Pepe, Sara Scalzulli, Emilia Mariggiò, Elena Latagliata, Roberto Guarini, Anna Foà, Robin |
author_sort | Puzzolo, Maria Cristina |
collection | PubMed |
description | A deep and stable molecular response (DMR) is a prerequisite for a successful treatment-free remission (TFR) in chronic myeloid leukemia (CML). In order to better identify and analyze potential candidates of successful TFR, we examined the phenotypic and functional host immune compartment in DMR patients who had received TKI treatment only (TKI-only) or had been previously treated with interferon-alpha (IFNα + TKI) or had received IFNα treatment only (IFNα-only). The T/NK-cell subset distribution, NK- and T-cell cytokine production, activation and maturation markers were measured in 44 patients in DMR treated with IFNα only (9), with IFNα + TKI (11) and with TKI-only (24). IFNα + TKI and TKI-only groups were eligible to TKI discontinuation according to the NCCN and ESMO guidelines (stable MR4 for more than two years). In IFNα-treated patients, we documented an increased number of lymphocytes capable of producing IFNγ and TNFα compared to the TKI-only group. In INFα + TKI patients, the percentage of NKG2C expression and its mean fluorescence intensity were significantly higher compared to the TKI-only group and to the INFα-only group in the CD56dim/CD16+ NK cell subsets (INFα + TKI vs. TKI-only p = 0.041, p = 0.037; INFα + TKI vs. INFα-only p = 0.03, p = 0.033, respectively). Furthermore, in INFα-only treated patients, we observed an increase of NKp46 MFI in the CD56bright/CD16- NK cell subset that becomes significant compared to the INFα + TKI group (p = 0.008). Our data indicate that a previous exposure to IFNα substantially and persistently modified the immune system of CML patients in memory T lymphocytes, differentiated NKG2C+ “long-lived” NK cells responses, even years after the last IFNα contact. |
format | Online Article Text |
id | pubmed-9570842 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-95708422022-10-17 Immunomodulatory Effects of IFNα on T and NK Cells in Chronic Myeloid Leukemia Patients in Deep Molecular Response Preparing for Treatment Discontinuation Puzzolo, Maria Cristina Breccia, Massimo Mariglia, Paola Colafigli, Gioia Pepe, Sara Scalzulli, Emilia Mariggiò, Elena Latagliata, Roberto Guarini, Anna Foà, Robin J Clin Med Article A deep and stable molecular response (DMR) is a prerequisite for a successful treatment-free remission (TFR) in chronic myeloid leukemia (CML). In order to better identify and analyze potential candidates of successful TFR, we examined the phenotypic and functional host immune compartment in DMR patients who had received TKI treatment only (TKI-only) or had been previously treated with interferon-alpha (IFNα + TKI) or had received IFNα treatment only (IFNα-only). The T/NK-cell subset distribution, NK- and T-cell cytokine production, activation and maturation markers were measured in 44 patients in DMR treated with IFNα only (9), with IFNα + TKI (11) and with TKI-only (24). IFNα + TKI and TKI-only groups were eligible to TKI discontinuation according to the NCCN and ESMO guidelines (stable MR4 for more than two years). In IFNα-treated patients, we documented an increased number of lymphocytes capable of producing IFNγ and TNFα compared to the TKI-only group. In INFα + TKI patients, the percentage of NKG2C expression and its mean fluorescence intensity were significantly higher compared to the TKI-only group and to the INFα-only group in the CD56dim/CD16+ NK cell subsets (INFα + TKI vs. TKI-only p = 0.041, p = 0.037; INFα + TKI vs. INFα-only p = 0.03, p = 0.033, respectively). Furthermore, in INFα-only treated patients, we observed an increase of NKp46 MFI in the CD56bright/CD16- NK cell subset that becomes significant compared to the INFα + TKI group (p = 0.008). Our data indicate that a previous exposure to IFNα substantially and persistently modified the immune system of CML patients in memory T lymphocytes, differentiated NKG2C+ “long-lived” NK cells responses, even years after the last IFNα contact. MDPI 2022-09-23 /pmc/articles/PMC9570842/ /pubmed/36233461 http://dx.doi.org/10.3390/jcm11195594 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Puzzolo, Maria Cristina Breccia, Massimo Mariglia, Paola Colafigli, Gioia Pepe, Sara Scalzulli, Emilia Mariggiò, Elena Latagliata, Roberto Guarini, Anna Foà, Robin Immunomodulatory Effects of IFNα on T and NK Cells in Chronic Myeloid Leukemia Patients in Deep Molecular Response Preparing for Treatment Discontinuation |
title | Immunomodulatory Effects of IFNα on T and NK Cells in Chronic Myeloid Leukemia Patients in Deep Molecular Response Preparing for Treatment Discontinuation |
title_full | Immunomodulatory Effects of IFNα on T and NK Cells in Chronic Myeloid Leukemia Patients in Deep Molecular Response Preparing for Treatment Discontinuation |
title_fullStr | Immunomodulatory Effects of IFNα on T and NK Cells in Chronic Myeloid Leukemia Patients in Deep Molecular Response Preparing for Treatment Discontinuation |
title_full_unstemmed | Immunomodulatory Effects of IFNα on T and NK Cells in Chronic Myeloid Leukemia Patients in Deep Molecular Response Preparing for Treatment Discontinuation |
title_short | Immunomodulatory Effects of IFNα on T and NK Cells in Chronic Myeloid Leukemia Patients in Deep Molecular Response Preparing for Treatment Discontinuation |
title_sort | immunomodulatory effects of ifnα on t and nk cells in chronic myeloid leukemia patients in deep molecular response preparing for treatment discontinuation |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9570842/ https://www.ncbi.nlm.nih.gov/pubmed/36233461 http://dx.doi.org/10.3390/jcm11195594 |
work_keys_str_mv | AT puzzolomariacristina immunomodulatoryeffectsofifnaontandnkcellsinchronicmyeloidleukemiapatientsindeepmolecularresponsepreparingfortreatmentdiscontinuation AT brecciamassimo immunomodulatoryeffectsofifnaontandnkcellsinchronicmyeloidleukemiapatientsindeepmolecularresponsepreparingfortreatmentdiscontinuation AT marigliapaola immunomodulatoryeffectsofifnaontandnkcellsinchronicmyeloidleukemiapatientsindeepmolecularresponsepreparingfortreatmentdiscontinuation AT colafigligioia immunomodulatoryeffectsofifnaontandnkcellsinchronicmyeloidleukemiapatientsindeepmolecularresponsepreparingfortreatmentdiscontinuation AT pepesara immunomodulatoryeffectsofifnaontandnkcellsinchronicmyeloidleukemiapatientsindeepmolecularresponsepreparingfortreatmentdiscontinuation AT scalzulliemilia immunomodulatoryeffectsofifnaontandnkcellsinchronicmyeloidleukemiapatientsindeepmolecularresponsepreparingfortreatmentdiscontinuation AT mariggioelena immunomodulatoryeffectsofifnaontandnkcellsinchronicmyeloidleukemiapatientsindeepmolecularresponsepreparingfortreatmentdiscontinuation AT latagliataroberto immunomodulatoryeffectsofifnaontandnkcellsinchronicmyeloidleukemiapatientsindeepmolecularresponsepreparingfortreatmentdiscontinuation AT guarinianna immunomodulatoryeffectsofifnaontandnkcellsinchronicmyeloidleukemiapatientsindeepmolecularresponsepreparingfortreatmentdiscontinuation AT foarobin immunomodulatoryeffectsofifnaontandnkcellsinchronicmyeloidleukemiapatientsindeepmolecularresponsepreparingfortreatmentdiscontinuation |